Home
Technology
About
Management Team
Contact Us
Home
Technology
About
Management Team
Contact Us
More
  • Home
  • Technology
  • About
  • Management Team
  • Contact Us
  • Home
  • Technology
  • About
  • Management Team
  • Contact Us

About

Kanyrpharma

 Kanyr was incorporated in May 2013.

​Acquired rights from McGill for two major cancer programs:
PRL-PTP inhibitor and ImmunyrTM technology.
​In the process of establishing seed funding.


Kanyr’s research team possesses over 15 years of experience in the PTP field.

​Is a “world-leader” in the understanding of how to chemically target PTP gene family. 


The PTP gene-family is associated with multiple human diseases but remains one of the few untapped areas of drug discovery. 

Unique opportunity

  PTPs have long been thought to be “undruggable”. Recent successes show that this is no longer the case.


The PTP inhibitor field is currently at the nascent stage. About the same as kinase inhibitors were 20 years ago. Kinase inhibitors are now a central part of modern medicine. 


Kanyr is focused on  three broadly applicable anti-cancer programs: PTP Inhibitor Immunotherapy – ImmunyrTM technology and PRL-PTP Inhibitors 

Copyright © 2023 Kanyrpharma - All Rights Reserved.

This website uses cookies.

We use cookies to analyze website traffic and optimize your website experience. By accepting our use of cookies, your data will be aggregated with all other user data.

Accept